Medicine Recommendations

Bipolar disorder

Epilepsy

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)

Unlicensed use for orthostatic intolerance disorders e.g. postural orthostatic tachycardia syndrome (PoTS)

Unlicensed use in Secretory Gastrointestinal Disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea)

Hyperphosphataemia (NICE CG157)

NICE CG157 - Hyperphosphataemia in chronic kidney disease: Management of hyperphosphataemia in patients with stage 4 or 5 chronic kidney disease

Please note Blackburn with Darwen & East Lancashire CCGs have more than one RAG status. Please consult local formulary

Rheumatic diseases

Treating chronic hyperuricaemia in people with gout (NICE TA506)

NICE TA506 - Lesinurad for treating chronic hyperuricaemia in people with gout

Breast cancer

NICE guideline NG101: Early and locally advanced breast cancer: diagnosis and management

Roundworm infections (unlicensed)

Epilepsy

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products   

Epilepsy

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Care in the last weeks or days of life - Nausea and vomiting in the last days of life AND Agitation/terminal restlessness in the last days of life

Nausea and vomiting

Opioid-induced nausea and vomiting

Schizophrenia (Existing Patients)

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

Schizophrenia (New Patients)

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

Contraception

MHRA Drug Safety Update - Intrauterine contraception: uterine perforation—updated information on risk factors

MHRA Drug Safety Update - Levonorgestrel-releasing intrauterine systems: prescribe by brand name

Use outside of the license of post-herpetic neuralgia for the treatment of localised neuropathic pain with predominance of allodynia and/or hyperalgesia and dysesthesias unresponsive to other neuropathic agents

Post Herpetic Neuralgia (as per LSCMMG Guidelines)

Treatment of primary premature ejaculation in adult men

 Moderate to severe irritable bowel syndrome with constipation

*FOR WEST LANCASHIRE ONLY* - Green for Second line option for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults